Format

Send to

Choose Destination
Curr Opin Pharmacol. 2017 Aug;35:66-74. doi: 10.1016/j.coph.2017.05.009. Epub 2017 Jun 14.

Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Author information

1
Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
2
Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK.
3
Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; Scientific and Technology Pole, IRCCS MultiMedica, Milan, Italy. Electronic address: douglas.noonan@uninsubria.it.

Abstract

Tumours elicit a number of mechanisms to induce a reprogramming of innate and adaptive immune cells to their advantage, inducing a pro-angiogenic phenotype. Investigation of these events is now leading to the identification of specific myeloid and lymphoid cell-targeted therapies, as well as of unexplored off-target activities of clinically relevant chemotherapeutic and metabolic drugs. It is also leading to an enhanced understanding of the interplay between angiogenesis and the immune system, and the value of novel co-targeting approaches using both immunotherapy and anti-angiogenic therapy. Here, we review recently identified mechanisms and potential pharmacological approaches targeting the crosstalk between cancer cells and the host immune system, providing an overview on novel therapeutic opportunities linking immuno-oncology and anti-angiogenic therapy.

PMID:
28623714
DOI:
10.1016/j.coph.2017.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center